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Available online 26 January 2016Abnormal monoamine oxidase A and B (MAO-A/B) activity and an imbalance in monoamine neurotransmitters
have been suggested to underlie the pathobiology of depression, a major psychiatric symptom observed in pa-
tients with neurodegenerative diseases, such as Huntington disease (HD). Increased MAO-A/B activity has
been observed in brain tissue from patients with HD and in human and rodent HD neural cells. Using the
YAC128 mouse model of HD, we studied the effect of an irreversible MAO-A inhibitor, clorgyline, on the levels
of select monoamine neurotransmitters associated with affective function. We observed a decrease in striatal
levels of the MAO-A/B substrates, dopamine and norepinephrine, in YAC128 HD mice compared with wild-
type mice, which was accompanied by increased anxiety- and depressive-like behaviour at ﬁve months of age.
Treatment for 26 dayswith clorgyline restored dopamine, serotonin, and norepinephrine neurotransmitter levels
in the striatum and reduced anxiety- and depressive-like behaviour in YAC128 HD mice. This study supports a
potential therapeutic use for MAO-A inhibitors in the treatment of depression and anxiety in patients with HD.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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Monoamines1. Introduction
Monoamine oxidases (MAO) play an important role in brain func-
tion via the metabolic regulation of monoamine neurotransmitters,
such as dopamine (DA), norepinephrine (NE), and serotonin (5-HT). Al-
terations in MAO activity, which are associated with changes in mono-
amine neurotransmitter levels as well as with the production of toxic
reactive oxygen species, have been implicated in the pathobiology of
neuropsychiatric and neurodegenerative disorders (Duncan et al.,
2012). Interestingly, psychiatric manifestations are a common feature
of many neurodegenerative disorders including Parkinson's (PD) and
Huntington disease (HD). Indeed, depression is the most prevalent
symptom in PD and HD, occurring in approximately 40–60% of patients
(Paulsen et al., 2005; Youdim and Bakhle, 2006).
Two isoforms of MAO exist, MAO-A and MAO-B, which share ap-
proximately 70% amino acid identity. Both proteins are expressed in
most mammalian tissues, associated with the outer membrane of theeneticMedicine, 8A Biomedical
@gmail.com (M.A. Pouladi).
. This is an open access article undermitochondria (Finberg, 2014; Youdim et al., 2006); however, the ratio
of MAO-A and MAO-B isoforms and the levels of MAO activity vary be-
tween regions of the human brain (Youdim et al., 2006). Enzymatically,
MAO-A andMAO-B differ in their substrate selectivity. NE and 5-HT are
speciﬁc substrates for MAO-A, whereas phenylethylamine (PEA) and
benzylamine are only degraded by MAO-B. DA is a common substrate
for both isozymes (Duncan et al., 2012).
Abnormal MAO-A and MAO-B activity are therefore involved in
distinct clinical presentations (Duncan et al., 2012). Dysregulation in
MAO-A activity has been implicated in a variety of neuropsychiatric
disorders including depression, anxiety, autism, and attention deﬁcit
hyperactivity disorder, whereas MAO-B activity, which has been de-
scribed to increase with ageing, is associated with neurodegenerative
disorders, such as PD (Duncan et al., 2012). Moreover, alterations in
bothMAO-A and B activity have been observed in brain regions that un-
dergo neurodegeneration in HD patients, such as the basal ganglia and
the pons (Richards et al., 2011).
Monoamine oxidase inhibitors have long been used for treatment of
psychiatric disorders and, more recently, have shown therapeutic bene-
ﬁts in the treatment of neurodegenerative disorders (Youdim and
Bakhle, 2006). MAO inhibitors can be classiﬁed as reversible orthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Youdim et al., 2006). Inhibition of MAO-A results in antidepressant
and anxiolytic effects (Cryan and Holmes, 2005; Finberg, 2014), where-
as selective MAO-B inhibitors are useful in movement disorders such as
PD (Finberg, 2014; Youdim andBakhle, 2006). AlthoughMAO inhibitors
have yet to be tested in the treatment of HD, the presence of psychiatric
manifestations and increasedMAO-A andMAO-B activity inHDpatients
suggest that MAO inhibitors may be of therapeutic beneﬁt.
Recently, we showed that inhibition of excessive MAO activity in
mouse and human HD neural cells using clorgyline, an irreversible
MAO-A inhibitor, reduces oxidative stress and improves cellular viabil-
ity (Ooi et al., 2015). These observations prompted us to evaluate the
effects of clorgyline further in the YAC128 (FVB/N) mouse model of
HD. The YAC128 HD mice express a full-length human mutant HTT
transgene and exhibit neuropathological and behavioural phenotypes
that mimic symptoms of patients with HD, including affective pheno-
types such depressive- and anxiety-like behaviour (Pouladi et al.,
2013; Slow et al., 2003). After establishing the appropriate dose of
clorgyline in wild-type (WT) FVB/N mice, we sought to determine the
effect of MAO-A inhibition on monoamine neurotransmitter levels and
affective phenotypes in YAC128 HD mice.
2. Material and methods
2.1. Animals
Three-month-old male FVB/N mice, purchased from InVivos
(Singapore), used for the initial clorgyline dosing study, and four-
month-old YAC128 HD and littermate wild-type mice were group-
housed on a reverse 12-h light/dark cycle. The mice had ad libitum ac-
cess to water and food throughout the study. Clorgyline hydrochloride
(Sigma) was diluted in phosphate buffered saline (PBS) and was deliv-
ered by intraperitoneal injection (i.p.) once per day. The diluteddrug so-
lution was free of precipitates. All animal procedures were reviewed
and approved by the Institutional Animal Care and Use Committee of
the Biological Resource Centre, ASTAR.
2.2. Drug treatment
For the clorgyline dosing study, 3 month old WTmice were divided
into four groups of 10 mice each. Three groups received clorgyline at a
dose of 0.5, 1.5, or 3 mg/kg and the fourth group received an equivalent
volume of PBS. For the YAC128 treatment study (Fig. 1A), three inde-
pendent cohorts of 4 month old mice were used, giving a total of
17–22 mice per treatment/group. For each cohort, mice were dividedFig. 1. Schematic representation of the experimental design for the clorgyline dosing study
in WT mice and efﬁcacy study in YAC128 HD mice. (A) WT mice were injected
intraperitoneally (i.p.) with vehicle (PBS) or clorgyline (0.5, 1.5, or 3 mg/kg) daily for
28 days. (B) WT mice were injected i.p. with vehicle (PBS) only, whereas YAC128 HD
mice were injected with either vehicle (PBS) or clorgyline (1.5 mg/kg), daily for 26 days.
For both (A) and (B), behavioural tests commenced on day 22 and were carried out in
this order: open ﬁeld (OF), elevated plus maze (EPM), tail suspension test (TST), and the
forced swim test (FST). Mice were sacriﬁced on day 26 or 28 and brain tissue was
harvested for biochemical assessments.into three groups. One group of YAC128 HD mice received clorgyline
at a dose of 1.5 mg/kg and two groups, one of WT mice and another
one of YAC128 HD mice, received an equivalent volume of PBS
(Fig. 1B). Treatments were administered daily before noon at a volume
of 10 mL/kg i.p. for 21 days and were continued throughout the behav-
ioural testing phase, which commenced on day 22. During the behav-
ioural testing phase, mice were treated in the afternoon following
completion of the corresponding behavioural test. Mice were sacriﬁced
once the behavioural testing was ﬁnished at day 26 or 28 (Fig. 1).2.3. Determination of MAO-A activity in brain tissue
TheMAO-Glo Assay System (Promega)was used tomeasureMAO-A
activity. Brain tissue was homogenized in lysis buffer (50 mM TRIS pH
8.0, 150 mM NaCl, 1% Igepal, 1× Roche complete proteinase inhibitor,
0.005 mM ZVAD, and 1 mM phenylmethulsulfonyl ﬂuoride in Milli-Q
water). Protein lysateswere diluted to 1mg/mL using lysis buffer. Dilut-
ed lysate (25 μL)was incubatedwith an equal volume of MAO substrate
solution (1:25 dilution of provided MAO substrate) for 2 h at room
temperature. Luciferin detection reagent (50 μL) was added and lumi-
nescence was measured using FLUOstar Omega plate reader (BMG
Labtech). Except for the lysis buffer, all solutions and reagents were
provided by the MAO-Glo Assay System (Promega).2.4. Determination of dopamine, norepinephrine, serotonin, and DOPAC
levels in brain tissues
Following completion of behavioural testing,micewere sacriﬁced by
carbon dioxide asphyxiation followed by rapid removal of the brains.
Brains weremicro-dissected on ice and immediately snap-frozen in liq-
uid nitrogen. DA, NE, and 5-HT were determined by Brains On-line
(Groningen, Netherlands) using established methods. Brieﬂy, for the
preparation of LC–MS samples, 6 mL of 0.5 M perchloric acid was
added to each mg of striatal tissue and the samples were homogenized
by sonication. The homogenates were centrifuged and the supernatants
were stored as brain extracts at−80 °C until analysis. For analysis, an
aliquot of internal standard solution was mixed with a diluted aliquot
of each brain extract sample. The mixture was centrifuged and the su-
pernatant was transferred to a vial suitable for use in the autosampler.
Concentrations of 5-HT, DA, NE, and DOPAC were determined by HPLC
with tandem mass spectrometry (MS/MS) detection, using deuterated
internal standards of the analytes. For each LC–MS sample, an aliquot
was injected onto the HPLC column by an automated sample injector
(SIL10-20 AC-HT, Shimadzu, Japan). Chromatographic separation was
performed on a SynergiMax column (100 × 3.0 mm, particle size
2.5 μm) held at a temperature of 35 °C. The mobile phases consisted of
A: ultra-puriﬁed H2O + 0.1% formic, and B: acetonitrile: ultra-puriﬁed
H2O (70:30) + 0.1% formic acid. Elution of the compounds proceeded
using a suitable linear gradient at a ﬂow rate of 0.3 mL/min. The
MS analyses were performed using an API 4000 MS/MS system
consisting of an API 4000 MS/MS detector and a Turbo Ion Spray inter-
face (Applied Biosystems, the Netherlands). The acquisitions on API
4000 were performed in positive ionisation mode, with optimised
settings for the analytes. The instrument was operated in multiple-
reaction-monitoring (MRM)mode. Datawere calibrated and quantiﬁed
using the Analyst data system (Applied Biosystems, version 1.6.2,
Netherlands). Concentrations in experimental samples were calculated
based on the calibration curve in the corresponding matrix.2.5. Behavioural tests of affective function
All behavioural testswere performed in themorning during the dark
phase of the reverse light/dark-cycle.
Fig. 2. Clorgyline treatment inhibitsMAO-A enzymatic activity and increases striatal levels
ofmonoamineneurotransmitters inWTmice. The three doses of clorgyline tested reduced
approximately 80% of MAO-A enzymatic activity in cortical tissue from clorgyline-treated
WT mice compared with vehicle-treated WT mice (A). MAO-A enzymatic inhibition
resulted in signiﬁcantly increased striatal levels of serotonin (B) and norepinephrine
(C) in clorgyline-treated WT mice. Whereas levels of dopamine (D) were unchanged,
striatal levels of DOPAC (E) were decreased after MAO-A enzymatic inhibition in
clorgyline-treated WT mice. No clorgyline dose-effect was observed in any of the
measures (A–E). (A) Values shown as percentage of vehicle-treated WT. Error bars
represent the standard error of the mean; n = 8–10 mice/treatment group;
****p b 0.0001 by one-way ANOVA with Tukey's post-hoc test analysis. (B–E) Values
shown as mean. Error bars represent the standard error of the mean; n = 8–10 mice/
treatment group; *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001 by one-way ANOVA
with Tukey's post-hoc test analysis.
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The open-ﬁeld test is commonly used to assess anxiety in rodents
(Crawley, 1985). The testing apparatus is a 50 × 50 cmopen, grey, acryl-
ic box (open ﬁeld) with 20-cm high walls. Because rodents have an in-
nate fear of open and bright spaces, they preferentially spendmore time
at the perimeter rather than the centre of the open ﬁeld. The time spent
in the centre versus the perimeter is taken as a measure of anxiety-like
behaviour. Test sessions lasted 10 min and the time spent in the centre
versus perimeter was recorded using an automated video-based track-
ing system (Noldus EthoVision 9, Netherlands).
2.5.2. Elevated plus maze test of anxiety
The Elevated Plus Maze (Walf and Frye, 2007) is a well-established
test of anxiety. The testing apparatus is shaped like a ‘+’ with two
open arms perpendicular to two closed arms of equal dimensions. The
closed arms are enclosed by three 10-cm high walls. Because rodents
have an innate fear of elevated open spaces, they tend to spend less
time in the open arms. Time spent in the open versus closed arms is
taken as a measure of anxiety-like behaviour. Generally, treatment of
rodents with anxiolytic drugs that reduce anxiety increases both the
amount of time spent in and the number of entries into the open arms
(Pellow et al., 1985). Test sessions lasted 5 min and the number of en-
tries into the open arms and time spent in the open versus closed
arms were recorded using an automated video-based tracking system
(Noldus EthoVision 9, Netherlands).
2.5.3. Tail-suspension test (TST) of depression
The TST was ﬁrst developed as a rodent screening test for potential
human antidepressant drugs, and was performed as previously de-
scribed (Cryan et al., 2005). Brieﬂy, mice were suspended by their tails
with adhesive tape attached to a suspension bar. The test sessions were
recorded by a video camera and each session lasted 6 min. Immobility
scores for each mouse were determined by manual scoring. The experi-
menters scoring the videos were blinded to the treatment and genotype.
Reduced mobility is considered a measure of depressive-like behaviour.
2.5.4. Porsolt forced swim test (FST) of depression
The Porsolt FST was performed as described previously (Pouladi
et al., 2009). Brieﬂy, mice were placed in individual cylinders (25 cm
tall × 19 cm wide) ﬁlled with room temperature water (23–25 °C) to
a depth of 15 cm for a period of 6 min. The test sessions were recorded
by a video camera placed directly above the cylinders. The sessionswere
examined blinded and the last 4min of the test sessionwas scored using
a time-sampling technique to rate the predominant behaviour over 5-s
intervals. The following behaviours were measured and recorded at the
end of every 5 s: swimming/climbing and immobility.
2.6. Statistical analysis
Data are expressed as means ± SEM. Statistical signiﬁcance was de-
termined by one- or two-way ANOVAwith appropriate post hoc testing,
or by Student's t test. Differences were considered statistically signiﬁ-
cant when p b 0.05.
3. Results
3.1. Effect of clorgyline on brainMAO-A enzymatic activity and striatal neu-
rotransmitter levels in wild-type mice
We ﬁrst assessed the effect of different doses of clorgyline treatment
(0.5, 1.5, or 3 mg/kg) on the enzymatic activity of MAO-A in the cortex
ofWTmice. Clorgyline treatment for 21 days resulted in a signiﬁcant in-
hibition of MAO-A enzymatic activity compared with vehicle-treated
animals (Fig. 2A; one-way ANOVA with Tukey's post hoc analysis;
p b 0.0001). All three doses tested resulted in a reduction of approxi-
mately 80% in enzymatic activity, and no signiﬁcant differences wereobserved between the three doses (Fig. 2A; one-way ANOVA with
Tukey's post hoc analysis; n.s.).
To examine the effect of MAO-A inhibition on the metabolism of
monoamine neurotransmitters, we assessed the levels of 5-HT, NE,
and DA, as well as the levels of 3,4-Dihydroxyphenylacetic acid
(DOPAC), the degradation product of dopamine, in the striatum of
vehicle-treated WT mice. Treatment with clorgyline at all tested doses
signiﬁcantly elevated striatal levels of 5-HT and NE compared with
vehicle-treated animals (Fig. 2B,C; one-way ANOVA with Tukey's post
hoc analysis; p b 0.0001 for 5-HT; p b 0.001 and p b 0.0001 for NE). In-
terestingly, DA levels remained unchanged (Fig. 2D), whereas DOPAC
levels were signiﬁcantly decreased in clorgyline-treated WT mice,
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of DA (Fig. 2E; one-way ANOVA with Tukey's post hoc analysis;
p b 0.001 and p b 0.0001).
3.2. Effect of clorgyline in tests of affective function
Having assessed the effect of different doses of clorgyline on
the levels of MAO-A activity and its monoamine neurotransmitter
substrates, we sought to evaluate the effect of clorgyline treatment on
affective function in WT mice.
First, we examined possible detrimental effects of clorgyline on WT
mice by measuring the body weight of all mice at the end of the
21 days of treatment. No signiﬁcant difference in body weight was ob-
served in mice treated with the low (0.5 mg/kg) and intermediate
(1.5 mg/kg) doses of clorgyline (one-way ANOVA with Tukey's post
hoc analysis; n.s.). However, treatment with the high dose (3 mg/kg)Fig. 3. Effect of clorgyline in tests of affective function. The clorgyline dose of 3 mg/kg
decreased body weight in WT mice whereas no effect was observed in the other doses
of clorgyline tested (A). In tests of anxiety-like behaviour, no effect of clorgyline was
observed in WT mice in the open-ﬁeld (B) and elevated plus maze (C) tests at any of
the doses tested. In tests of depressive like-behaviour, WT mice treated with the highest
dose of clorgyline (3 mg/kg) spent less time immobile in the tail suspension test (D),
but no effect of clorgyline was observed in the forced swim test (E). (A–E) Values
shownasmean. Error bars represent the standard error of themean;n=8–10mice/treat-
ment group; **p b 0.01 by one-way ANOVA with Tukey's post-hoc test analysis.resulted in a signiﬁcant loss of body weight when compared with
vehicle-treated mice (Fig. 3A; one-way ANOVA with Tukey's post hoc
analysis; p b 0.05), suggesting a potentially detrimental effect of the
highest dose of clorgyline on WT mice.
We then assessed the effect of clorgyline on mouse anxiety levels
using the open ﬁeld (OF) and elevated plus maze (EPM) tests of
anxiety-like behaviour. Clorgyline treatment had no effect on perfor-
mance in these tests; time spent in the centre of the arena of the OF
and in the open arms of the EPM were similar between the clorgyline-
and vehicle-treated mice (Fig. 3B, C).
Next, we assessed depressive-like phenotypes using the tail suspen-
sion test (TST) and Porsolt forced swim test (FST). In the TST,mice treat-
ed with the high dose of clorgyline showed a signiﬁcant decrease
in depressive-like behaviour (immobility) compared with vehicle-
treated mice (Fig. 3D). Clorgyline had no effect on performance in the
FST at any of the doses tested (Fig. 3E).
These data indicate that clorgyline did not have a detrimental effect
on anxiety- and depressive-like behaviour at any of the doses tested
(Fig. 3B-E). However, because the highest dose of clorgyline (3 mg/kg)
resulted in body weight loss, we chose the intermediate dose
(1.5 mg/kg), the highest dose tested that did not cause detrimental ef-
fects, to evaluate the effect of clorgyline in the YAC128 mouse model
of HD. To ensure similar pharmacokinetics of clorgyline in WT and
YAC128 mice, we measured plasma levels of clorgyline following treat-
ment and foundnodifference between the genotypes (data not shown).
3.3. Clorgyline treatment inhibits MAO-A activity and rescues striatal neu-
rotransmitter deﬁcits in YAC128 HD mice
Clorgyline treatment (1.5mg/kg for 21 days) inhibitedMAO-A enzy-
matic activity in cortical tissue from YAC128 HDmice by approximatelyFig. 4.MAO-A enzymatic inhibition by clorgyline rescues striatal neurotransmitter deﬁcits
in YAC128 HD mice. Striatal serotonin levels (A) were decreased in vehicle-treated
YAC128 HD mice compared to vehicle-treated WT mice, whereas norepinephrine
(B) and dopamine (C) striatal levels were signiﬁcantly lower. Clorgyline treatment
signiﬁcantly increased serotonin (A) levels and rescued norepinephrine (B) and
dopamine (C) levels in the striatum of clorgyline-treated YAC128 HD mice. (A–C) Values
shown were normalized to vehicle-treated WT. Error bars represent the standard
error of the mean; n = 18–21 vehicle-treated WT, n = 12–15 vehicle-treated YAC128,
n = 18 clorgyline-treated YAC128 (three independent cohorts); *p b 0.05, **p b 0.01,
****p b 0.0001 by paired two-tailed student t-test.
Fig. 5. Clorgyline treatment improves affective function in YAC128 HD mice. Clorgyline-
treated YAC128 HD mice did not show changes in body weight compared with YAC128-
vehicle HD mice (A). In tests of anxiety-like behaviour, YAC128-vehicle mice presented
anxiety-like phenotypes in the open ﬁeld (B) and elevated plus maze (C) tests compared
with WT-vehicle mice. Clorgyline treatment ameliorated the anxiety-like deﬁcits
observed in the YAC128 HD mice (B-C). In tests of depressive-like behaviour, vehicle-
treated YAC128 HD mice exhibited depressive-like phenotypes in the Porsolt forced swim
test (E) but not in the tail suspension test (D) compared with vehicle-treated WT mice.
Clorgyline treatment reduced the time that YAC128 HD mice spent immobile in the tail
suspension test (D), but no effect was observed in the forced swim test (E). (A–E) Values
shown were normalized to vehicle-treated WT mice. Error bars represent the standard
error of the mean; n = 19–21 vehicle-treated WT, n = 17–20 vehicle-treated YAC128,
n= 21–22 clorgyline-treated YAC128 (three independent cohorts); *p b 0.05, **p b 0.01,
***p b 0.001, ****p b 0.0001 by paired two-tailed student t-test.
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tailed student t-test; p = 8.98 × 10−5). Striatal DA and NE levels were
also signiﬁcantly reduced in YAC128 HD mice compared with WT
mice (Fig. 4B,C; paired two-tailed student t-test; p = 0.004 for DA and
p = 0.0018 for NE) however striatal 5-HT was not signiﬁcantly altered
in YAC128 HD mice compared with WT mice (Fig. 4A; paired two-
tailed student t-test; ns). In clorgyline-treated YAC128 HDmice, striatal
levels of all three neurotransmitters were signiﬁcantly elevated in com-
parison with vehicle-treated YAC128 HDmice (Fig. 4; paired two-tailed
student t-test; p= 7× 10−4 for 5-HT; p= 3 × 10−6 for NE; p= 0.0158
for DA). Striatal 5-HT and NE levels were signiﬁcantly elevated in treat-
ed YAC128 HD mice compared to vehicle-treated WT mice (Fig. 4A, B;
paired two-tailed student t-test; p = 2 × 10−5 for 5-HT; p =
8 × 10−5 for NE; p = 0.45 for DA). To test the speciﬁcity of MAO-A in-
hibition by clorgyline, striatal levels of PEA, a speciﬁc MAO-B substrate,
were also measured. No differences in striatal PEA were observed be-
tween vehicle- and clorgyline-treated YAC128 HD mice, suggesting
lack of MAO-B inhibition (data not shown).
3.4. Clorgyline treatment improves affective function in YAC128 mice
Mouse models of HD, including the YAC128 HD model, show affec-
tive phenotypes, such as anxiety and depression (Pouladi et al., 2013,
2009, 2012b). Given thewell-established relationship between changes
in monoamine neurotransmitter levels and affective phenotypes, we
evaluated the effect of clorgyline on behavioural measures of depres-
sion and anxiety in YAC128 HD mice. We found no difference in the
body weight of clorgyline- and vehicle-treated YAC128 HD mice at
the end of the 21-day treatment (Fig. 5A; paired two-tailed student
t-test; p = 0.523), suggesting no detrimental effects of clorgyline
treatment.
YAC128 HDmice showed an increased anxiety-like phenotype, signi-
ﬁed by shorter time periods spent in the centre of the arena in the OF test
and in the open arms of the EPM, compared with WT mice (Fig. 5B,C;
paired two-tailed student t-test; p = 3 × 10−4 for OF and p =
2 × 10−5 for EPM). YAC128 HD mice also displayed depressive-like be-
haviour in the Porsolt FST, as shown by the increased immobility
observed compared with WT mice (Fig. 5E; paired two-tailed student
t-test; p = 6 × 10−4). Performance in the TST was unaltered in HD
mice compared with WT (Fig. 5D; paired two-tailed student t-test;
p = 0.731).
Clorgyline treatment improved anxiety-like phenotypes, signiﬁcantly
increasing the amount of time spent in the centre of the arena in the OF
test and in the open arms of the EPM (Fig 5B,C; paired two-tailed
student t-test; p = 0.0063 for OF, p = 0.0315 for EPM). Decreased
immobility times were also observed in the TST, but not the FST,
indicating a reduction in depressive-like behaviour (Fig. 5D,E; paired
student t-test; p = 0.029 for TST).
4. Discussion
Psychiatric manifestations are a common feature of HD (Rosenblatt,
2007). While social and psychological factors are thought to play a role
(Paulsen et al., 2005), ﬁndings from human and animal studies strongly
implicate neurobiological alterations related to the HD mutation in the
aetiology of psychiatric disturbances of HD (Pouladi et al., 2009). Al-
though the aetiology of depression in HD remains poorly understood,
several pathogenic mechanisms have been proposed, including deﬁ-
cient brain-derived neurotrophic factor (BDNF) and neurotrophin sig-
nalling, a hyperactive hypothalamic–pituitary–adrenal (HPA) axis, and
impaired hippocampal neurogenesis (Ben M'Barek et al., 2013; Du
et al., 2013). In addition to these abnormalities (Pouladi et al., 2012a;
Simpson et al., 2011), we now demonstrate that YAC128 HD mice ex-
hibit deﬁcits in monoamine neurotransmitters known to be tightly as-
sociated with affective disorders (Hamon and Blier, 2013; Lanni et al.,
2009). We further show that elevating the levels of these monoamines,namely serotonin, norepinephrine, and dopamine, by pharmacological
inhibition of MAO-A improves affective phenotypes of YAC128 HD
mice. These ﬁndings suggest that monoaminergic impairments may
be a contributing factor to the psychiatric manifestations of HD.
Deﬁcits in dopaminergic signalling have been demonstrated in pre-
symptomatic gene carriers, symptomatic patients, and animal models of
HD (Callahan and Abercrombie, 2011; Cha et al., 1999; Chen et al.,
2013; Mochel et al., 2011; Pavese et al., 2003, 2010; Renoir et al., 2014).
Similarly, there is evidence for serotonergic dysfunction in rodentmodels
and in patients with HD (Jahanshahi et al., 2013; Manyam, 1973; Mochel
et al., 2011; Pang et al., 2008; Renoir et al., 2011; Rosas et al., 2015). Treat-
ments targeting the dopamine-norepinephrine (Renoir et al., 2012) and
the serotonin systems (Pang et al., 2008) have been shown to improve
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contribute to affective abnormalities. Interestingly, improvements in af-
fective phenotypes resulting from targeting the serotonergic system
have been observed in rodents expressing an N-terminus fragment of
mutant HTT (Pang et al., 2008) but not those expressing the full length
HTT protein (Hult Lundh et al., 2013; Pouladi et al., 2009). Serotonergic
deﬁcits may therefore bemore important in the development of affective
phenotypes in HTT N-terminus fragment models, which generally have a
more rapid onset.
In addition to our ﬁndings with clorgyline, an MAO-A inhibitor, treat-
mentswith themood stabilizers, lithiumandvalproate, have also been re-
ported to improve affective phenotypes in YAC128 HD mice (Chiu et al.,
2011). Indeed, valproate treatment improved performance in the FST
and TST tests of depression, and combined valproate and lithium treat-
ment improved performance in the FST, TST, as well as the open-ﬁeld
test of anxiety (Chiu et al., 2011). These improvements were accompa-
nied by altered GSK-3beta activation, histone H3 acetylation, and im-
proved expression of HSP70, BDNF, and its cognate receptor TrkB,
which may have contributed to the observed improvements (Chiu et al.,
2011). Thus, multiple pathogenic mechanisms may underlie affective
dysfunction inHD.While it would be tempting to speculate about the rel-
ative contribution of these pathways and hence the therapeutic value of
engaging each in isolation on affective phenotypes in HD, a combinatorial
treatment strategy is likely to yield greater beneﬁt, and determining the
optimal combination of therapeutic agents should be the subject of future
studies.
It should be noted that at the dose chosen in this study, clorgyline
treatment elevated serotonin and norepinepherine in YAC128 HD mice
to levels higher than those seen in WT mice. This observation highlights
the need for appropriate dose titration to ensure that neurotransmitters
affected in HD are restored without overtly exceeding the normal range
and risking undesirable side effects such as the serotonin syndrome
(Iqbal et al., 2012).
Several factors may contribute to the deﬁcits in the levels of striatal
monoamine neurotransmitters observed in YAC128 HDmice. The rescue
of neurotransmitter levels we observed following clorgyline treatment
supports a role for MAO-A. Dysregulation of MAO-A/B activity has been
linked not only to depression but also to neurodegenerative disorders. In-
deed, increased MAO-A/B activity has been observed in patients with HD
in brain regions that undergo neurodegeneration (Richards et al., 2011)
and inhumanneural cells differentiated fromHDpatient-derived induced
pluripotent stem cells (Ooi et al., 2015). It is plausible that monoamine
deﬁcits reﬂect altered biosynthesis, although this requires further
investigation.
There is considerable variability in the nature, severity, and timing
of appearance of psychiatric symptoms in HD (Rosenblatt, 2007; van
Duijn et al., 2007). While this variability may, in part, reﬂect poor
standardisation of the diagnostic criteria used to assess psychiatric fea-
tures, it also points to a likely role for environmental (Nithianantharajah
and Hannan, 2006), epigenetic (Glajch and Sadri-Vakili, 2015), and ge-
netic modiﬁers (Consortium et al., 2015). Genetic polymorphisms and
epigenetic variation inMAOA have been associated with altered MAO-
A levels and activity (Naoi et al., 2015; Sabol et al., 1998; Shumay
et al., 2012) as well as psychiatric disorders, including depression, ag-
gression, and anxiety (Buckholtz and Meyer-Lindenberg, 2008; Naoi
et al., 2015). Furthermore, MAO-A expression has been shown to be re-
sponsive to certain environmental factors (Naoi et al., 2015). Thus both
genetic and epigenetic variation inMAOAmay contribute to psychiatric
manifestations in HD.
The results fromour study support a role formonoaminergic impair-
ments in the affective phenotypes observed in YAC128 HD mice, and
suggest potential therapeutic beneﬁts ofMAO-A inhibitors for the treat-
ment of psychiatric abnormalities in HD. Our ﬁndings also raise the
question of whether targeting monoaminergic impairments in HD
may improve symptoms beyond psychiatric abnormalities, including
deﬁcits in motor function and cognition.Acknowledgements
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